For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed drug updates.

Drug Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

FDA data

Drug Reference

Drug approvals, labels, and clinical context.

Access structured FDA label data, dosage references, NDC records, interactions, and prescribing context.

Clinical Coverage

Additional Drug Updates

Rheumatology

FDA Approves Deucravacitinib for Psoriatic Arthritis: TYK2 Inhibition Reduces Disease Activity

May 12|3 min read|By Dr. Deepak Nair
Endocrinology

FDA Approves Langlara: New Biosimilar Insulin for Cost-Effective Diabetes Management

May 12|3 min read|By Dr. Amit Desai
Endocrinology

FDA Approves Afrezza for Pediatric Use: First Needle-Free Insulin for Kids Ages 4 and Up

May 12|3 min read|By Dr. Amit Desai
Oncology

FDA Approves Vepdegestrant for ESR1-Mutated Breast Cancer: 5-Month PFS Improvement

May 12|3 min read|By Dr. Meera Pillai
Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: Novel Treatment Algorithm for Seronegative Cases

May 12|3 min read|By Dr. Aditi Kulkarni
Otolaryngology

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis in Adults and Children 6 Years and Older

May 12|3 min read|By Editorial Team
Infectious Disease

FDA Expands Arexvy Indication for RSV: Now Approved for Immunocompromised Adults Aged 18 to 49

May 12|3 min read|By Dr. Simran Kohli
Endocrinology

WHO Releases 2026 Guidelines for GLP-1 Therapies in Obesity Management

May 12|3 min read|By Dr. Amit Desai
Infectious Disease

FDA Approves Arexvy for RSV Prevention: Expanded Indication for High-Risk Adults 18-49

May 12|3 min read|By Dr. Simran Kohli
Rheumatology

Deucravacitinib vs IL-17 and IL-23 Inhibitors: A Comparison for Psoriatic Arthritis Management

May 12|3 min read|By Dr. Deepak Nair
Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for AChR Negative Patients

May 12|3 min read|By Dr. Vikram Patel
Cardiology

Baxdrostat Targets Aldosterone Pathway: New Algorithm for Resistant Hypertension Management

May 12|3 min read|By Dr. Kavya Sharma
Infectious Disease

COVID-19 Post-Exposure Prevention: Ensitrelvir vs Paxlovid vs No Treatment

May 12|3 min read|By Dr. Simran Kohli
Infectious Disease

CDC Updates RSV Vaccine Guidelines: Arexvy Recommended for High-Risk Adults 18-49

May 12|3 min read|By Dr. Simran Kohli
Neurology

FDA Approves Glatiramer Acetate Biosimilar for Relapsing MS: First Complex Injectable Generic

May 9|3 min read|By Dr. Vikram Patel
Endocrinology

FDA Proposes Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List

May 9|3 min read|By Dr. Amit Desai
Rare Disease

FDA Approves Marnetegragene Autotemcel for Severe LAD-I in Pediatrics

May 9|3 min read|By Editorial Team
Endocrinology

FDA Approves Orforglipron for Obesity: Oral GLP-1 Therapy with No Food Restrictions

May 9|3 min read|By Dr. Amit Desai
Endocrinology

FDA Approves Afrezza for Pediatric Use: First Needle-Free Insulin for Children with Diabetes

May 9|3 min read|By Dr. Amit Desai
Neurology

FDA Approves Donanemab for Alzheimer: Subcutaneous Dosing Options Available

May 9|3 min read|By Dr. Vikram Patel
Obstetrics Gynecology

FDA Issues Guidance for Improved Pregnancy Safety Data Collection: Implications for Drugs and Biologics

May 9|3 min read|By Editorial Team
Endocrinology

FDA Approves Langlara and Ponlimsi: New Biosimilars for Insulin Access

May 9|3 min read|By Dr. Amit Desai
Endocrinology

FDA Proposes Exclusion of Semaglutide and Tirzepatide from 503B Bulks List: Impact on Compounding Access

May 9|3 min read|By Dr. Amit Desai